Shopping Cart 0
Cart Subtotal
USD 0

3SBio Inc (1530) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

3SBio Inc (3SBio) is a biotechnology companies that carries out the research, development, manufacturing and marketing of biopharmaceutical products. It develops recombinant, or genetically engineered, protein-based products and other pharmaceutical product candidates to address large markets with significant unmet medical needs in the areas of cancer and its supportive care, nephrology, dermatology and other therapeutic areas. the company's products are distributed to hospitals, clinics and dialysis centers across China. The company's products are approved for sale in Colombia, Brazil, Costa Rica, Egypt, Dominican Republic, Guatemala, El Salvador, Mongolia, Laos, Pakistan, Sri Lanka, Myanmar, Philippines, Paraguay, Thailand and Trinidad and Tobago. 3SBio is headquartered in Shenyang, China.

3SBio Inc (1530)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

3SBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

3SBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

3SBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

3SBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

3SBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

3SBio Inc, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

3SBio Acquires Anti-TNF Monoclonal Antibody Technology from Apexigen 11

3SBio Acquires Patents For DJ5, Potential Renal Failure Therapy, From SIMM 12

Venture Financing 13

Refuge Biotech Raises USD25 Million in Series B Financing 13

Private Equity 15

3SBio CEO And Citic Private Equity Funds Complete Acquisition Of 3SBio 15

Partnerships 17

Refuge Biotechnologies Enters into Agreement with 3SBio 17

3SBio and CPE Funds to Form Joint Venture 18

3SBio Enters into Distribution Agreement with Eli Lilly 19

TNK Therapeutics to Form Joint Venture with Shenyang Sunshine Pharma 20

3SBio Enters Into Strategic Alliance with Ascentage Pharma 21

3SBio Enters Into Joint Venture Agreement With DaVita For Dialysis Treatment 22

Licensing Agreements 23

3SBio Enters into Licensing Agreement with Alteogen 23

3SBio Enters into Licensing Agreement with PharmAbcine for DIG-KT 24

3SBio Enters into Licensing Agreement with PharmAbcine for Tanibirumab 25

3SBio Enters into Licensing Agreement with JenKem for PEG-Irinotecan 26

3SBio Enters into Licensing Agreement with DiNonA for Leukotuximab 27

Selecta Biosciences Enters into Licensing Agreement with 3SBio for Pegsiticase 28

Equity Offering 29

3SBio Completes Private Placement 29

3SBio Raises USD569 Million in IPO 30

Acquisition 31

3SBio Acquires 47% Stake in Shanghai CP Guojian Pharma for USD214 Million 31

3SBio Acquires Zhejiang Wansheng Pharma for USD86 Million 32

3SBio Acquires Sciprogen 33

3SBio Acquires Sirton Pharma 34

3SBio Inc-Key Competitors 35

3SBio Inc-Key Employees 36

3SBio Inc-Locations And Subsidiaries 37

Head Office 37

Other Locations & Subsidiaries 37

Recent Developments 39

Corporate Communications 39

Jan 09, 2017: 3SBio Appoints Dr. Zhenping Zhu as President of Research & Development and Chief Scientific Officer 39

Appendix 40

Methodology 40

About GlobalData 40

Contact Us 40

Disclaimer 40


List Of Figure

List of Figures

3SBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

3SBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

3SBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

3SBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

3SBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

3SBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

3SBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

3SBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

3SBio Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

3SBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

3SBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

3SBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

3SBio Inc, Deals By Therapy Area, 2012 to YTD 2018 8

3SBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

3SBio Acquires Anti-TNF Monoclonal Antibody Technology from Apexigen 11

3SBio Acquires Patents For DJ5, Potential Renal Failure Therapy, From SIMM 12

Refuge Biotech Raises USD25 Million in Series B Financing 13

3SBio CEO And Citic Private Equity Funds Complete Acquisition Of 3SBio 15

Refuge Biotechnologies Enters into Agreement with 3SBio 17

3SBio and CPE Funds to Form Joint Venture 18

3SBio Enters into Distribution Agreement with Eli Lilly 19

TNK Therapeutics to Form Joint Venture with Shenyang Sunshine Pharma 20

3SBio Enters Into Strategic Alliance with Ascentage Pharma 21

3SBio Enters Into Joint Venture Agreement With DaVita For Dialysis Treatment 22

3SBio Enters into Licensing Agreement with Alteogen 23

3SBio Enters into Licensing Agreement with PharmAbcine for DIG-KT 24

3SBio Enters into Licensing Agreement with PharmAbcine for Tanibirumab 25

3SBio Enters into Licensing Agreement with JenKem for PEG-Irinotecan 26

3SBio Enters into Licensing Agreement with DiNonA for Leukotuximab 27

Selecta Biosciences Enters into Licensing Agreement with 3SBio for Pegsiticase 28

3SBio Completes Private Placement 29

3SBio Raises USD569 Million in IPO 30

3SBio Acquires 47% Stake in Shanghai CP Guojian Pharma for USD214 Million 31

3SBio Acquires Zhejiang Wansheng Pharma for USD86 Million 32

3SBio Acquires Sciprogen 33

3SBio Acquires Sirton Pharma 34

3SBio Inc, Key Competitors 35

3SBio Inc, Key Employees 36

3SBio Inc, Other Locations 37

3SBio Inc, Subsidiaries 37

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

3SBio Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

3SBio Inc (3SBio) is a biotechnology companies that carries out the research, development, manufacturing and marketing of biopharmaceutical products. It develops recombinant, or genetically engineered, protein-based products and other pharmaceutical product candidates to address large markets with significant unmet medical needs in the areas of cancer and its supportive care, nephrology, dermatology and other therapeutic areas. the company's products are distributed to hospitals, clinics and dialysis centers across China. The company's products are approved for sale in Colombia, Brazil, Costa Rica, Egypt, Dominican Republic, Guatemala, El Salvador, Mongolia, Laos, Pakistan, Sri Lanka, Myanmar, Philippines, Paraguay, Thailand and Trinidad and Tobago. 3SBio is headquartered in Shenyang, China.

3SBio Inc (1530)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

3SBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

3SBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

3SBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

3SBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

3SBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

3SBio Inc, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

3SBio Acquires Anti-TNF Monoclonal Antibody Technology from Apexigen 11

3SBio Acquires Patents For DJ5, Potential Renal Failure Therapy, From SIMM 12

Venture Financing 13

Refuge Biotech Raises USD25 Million in Series B Financing 13

Private Equity 15

3SBio CEO And Citic Private Equity Funds Complete Acquisition Of 3SBio 15

Partnerships 17

Refuge Biotechnologies Enters into Agreement with 3SBio 17

3SBio and CPE Funds to Form Joint Venture 18

3SBio Enters into Distribution Agreement with Eli Lilly 19

TNK Therapeutics to Form Joint Venture with Shenyang Sunshine Pharma 20

3SBio Enters Into Strategic Alliance with Ascentage Pharma 21

3SBio Enters Into Joint Venture Agreement With DaVita For Dialysis Treatment 22

Licensing Agreements 23

3SBio Enters into Licensing Agreement with Alteogen 23

3SBio Enters into Licensing Agreement with PharmAbcine for DIG-KT 24

3SBio Enters into Licensing Agreement with PharmAbcine for Tanibirumab 25

3SBio Enters into Licensing Agreement with JenKem for PEG-Irinotecan 26

3SBio Enters into Licensing Agreement with DiNonA for Leukotuximab 27

Selecta Biosciences Enters into Licensing Agreement with 3SBio for Pegsiticase 28

Equity Offering 29

3SBio Completes Private Placement 29

3SBio Raises USD569 Million in IPO 30

Acquisition 31

3SBio Acquires 47% Stake in Shanghai CP Guojian Pharma for USD214 Million 31

3SBio Acquires Zhejiang Wansheng Pharma for USD86 Million 32

3SBio Acquires Sciprogen 33

3SBio Acquires Sirton Pharma 34

3SBio Inc-Key Competitors 35

3SBio Inc-Key Employees 36

3SBio Inc-Locations And Subsidiaries 37

Head Office 37

Other Locations & Subsidiaries 37

Recent Developments 39

Corporate Communications 39

Jan 09, 2017: 3SBio Appoints Dr. Zhenping Zhu as President of Research & Development and Chief Scientific Officer 39

Appendix 40

Methodology 40

About GlobalData 40

Contact Us 40

Disclaimer 40


List Of Figure

List of Figures

3SBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

3SBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

3SBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

3SBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

3SBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

3SBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

3SBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

3SBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

3SBio Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

3SBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

3SBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

3SBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

3SBio Inc, Deals By Therapy Area, 2012 to YTD 2018 8

3SBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

3SBio Acquires Anti-TNF Monoclonal Antibody Technology from Apexigen 11

3SBio Acquires Patents For DJ5, Potential Renal Failure Therapy, From SIMM 12

Refuge Biotech Raises USD25 Million in Series B Financing 13

3SBio CEO And Citic Private Equity Funds Complete Acquisition Of 3SBio 15

Refuge Biotechnologies Enters into Agreement with 3SBio 17

3SBio and CPE Funds to Form Joint Venture 18

3SBio Enters into Distribution Agreement with Eli Lilly 19

TNK Therapeutics to Form Joint Venture with Shenyang Sunshine Pharma 20

3SBio Enters Into Strategic Alliance with Ascentage Pharma 21

3SBio Enters Into Joint Venture Agreement With DaVita For Dialysis Treatment 22

3SBio Enters into Licensing Agreement with Alteogen 23

3SBio Enters into Licensing Agreement with PharmAbcine for DIG-KT 24

3SBio Enters into Licensing Agreement with PharmAbcine for Tanibirumab 25

3SBio Enters into Licensing Agreement with JenKem for PEG-Irinotecan 26

3SBio Enters into Licensing Agreement with DiNonA for Leukotuximab 27

Selecta Biosciences Enters into Licensing Agreement with 3SBio for Pegsiticase 28

3SBio Completes Private Placement 29

3SBio Raises USD569 Million in IPO 30

3SBio Acquires 47% Stake in Shanghai CP Guojian Pharma for USD214 Million 31

3SBio Acquires Zhejiang Wansheng Pharma for USD86 Million 32

3SBio Acquires Sciprogen 33

3SBio Acquires Sirton Pharma 34

3SBio Inc, Key Competitors 35

3SBio Inc, Key Employees 36

3SBio Inc, Other Locations 37

3SBio Inc, Subsidiaries 37

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

3SBio Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.